National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov

Search for Clinical Trials at NIH

The National Cancer Institute (NCI) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 7 clinical trials at NIH that match your search criteria


  • Cancer by PI: Kreitman, Robert J. M.D.

  
Trial and Protocol Number
Leukemia (Adult)
Principal InvestigatorReferral Contact
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
NCI-09-C-0025
Robert J. Kreitman
301-496-6947
Linda Ellison
301-496-9458
ellisonl@mail.nih.gov
Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease
NCI-09-C-0005
Robert J. Kreitman
301-496-6947
Linda Ellison
301-496-9458
ellisonl@mail.nih.gov
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia
NCI-07-C-0130
Robert J. Kreitman
301-496-6947
Linda Ellison
301-496-9458
ellisonl@mail.nih.gov
Phase II Study of LMB-2 Immunotoxin in Patients With Recurrent or Refractory CD25-Positive Hairy Cell Leukemia
NCI-06-C-0150
Robert J. Kreitman
301-496-6947
Linda Ellison
301-496-9458
ellisonl@mail.nih.gov
Phase II Study of LMB-2 Immunotoxin in Patients With CD25-Positive Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
NCI-04-C-0121
Robert J. Kreitman
301-496-6947
Linda Ellison
301-496-9458
ellisonl@mail.nih.gov
Phase II Trial of BL22 Immunotoxin in Hairy Cell Leukemia
NCI-04-C-0014
Robert J. Kreitman
301-496-6947
Linda Ellison
301-496-9458
ellisonl@mail.nih.gov


  
Trial and Protocol Number
Lymphoma, Cutaneous T-cell (CTCL)
Principal InvestigatorReferral Contact
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas
NCI-04-C-0142
Robert J. Kreitman
301-496-6947
Linda Ellison
301-496-9458
ellisonl@mail.nih.gov


If there are no studies listed for your specific disease type, please search under:

Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov National Cancer Institute Clinical Trials at NIH - Be part of the cure